X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ALEMBIC PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ALEMBIC PHARMA AUROBINDO PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 13.8 15.1 91.5% View Chart
P/BV x 3.0 3.5 86.4% View Chart
Dividend Yield % 0.4 1.1 38.0%  

Financials

 AUROBINDO PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ALEMBIC PHARMA
Mar-19
AUROBINDO PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs809664 121.8%   
Low Rs504412 122.2%   
Sales per share (Unadj.) Rs281.1208.7 134.7%  
Earnings per share (Unadj.) Rs41.431.0 133.4%  
Cash flow per share (Unadj.) Rs50.937.1 137.1%  
Dividends per share (Unadj.) Rs2.505.50 45.5%  
Dividend yield (eoy) %0.41.0 37.3%  
Book value per share (Unadj.) Rs199.4144.2 138.2%  
Shares outstanding (eoy) m585.88188.52 310.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.6 90.6%   
Avg P/E ratio x15.917.4 91.4%  
P/CF ratio (eoy) x12.914.5 89.0%  
Price / Book Value ratio x3.33.7 88.2%  
Dividend payout %6.017.7 34.1%   
Avg Mkt Cap Rs m384,630101,461 379.1%   
No. of employees `00017.3NA-   
Total wages/salary Rs m21,3087,467 285.4%   
Avg. sales/employee Rs Th9,500.7NM-  
Avg. wages/employee Rs Th1,229.4NM-  
Avg. net profit/employee Rs Th1,397.9NM-  
INCOME DATA
Net Sales Rs m164,66639,347 418.5%  
Other income Rs m1,02094 1,087.2%   
Total revenues Rs m165,68639,441 420.1%   
Gross profit Rs m37,7188,736 431.8%  
Depreciation Rs m5,5801,152 484.2%   
Interest Rs m777184 422.2%   
Profit before tax Rs m32,3807,493 432.1%   
Minority Interest Rs m3111 290.7%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1831,568 522.0%   
Profit after tax Rs m24,2295,844 414.6%  
Gross profit margin %22.922.2 103.2%  
Effective tax rate %25.320.9 120.8%   
Net profit margin %14.714.9 99.1%  
BALANCE SHEET DATA
Current assets Rs m121,87819,577 622.5%   
Current liabilities Rs m86,80614,896 582.7%   
Net working cap to sales %21.311.9 179.0%  
Current ratio x1.41.3 106.8%  
Inventory Days Days13090 144.7%  
Debtors Days Days6845 150.8%  
Net fixed assets Rs m81,03727,097 299.1%   
Share capital Rs m586377 155.4%   
"Free" reserves Rs m116,21826,811 433.5%   
Net worth Rs m116,80427,188 429.6%   
Long term debt Rs m4,5124,993 90.4%   
Total assets Rs m211,05247,778 441.7%  
Interest coverage x42.741.7 102.3%   
Debt to equity ratio x00.2 21.0%  
Sales to assets ratio x0.80.8 94.7%   
Return on assets %11.812.6 93.9%  
Return on equity %20.721.5 96.5%  
Return on capital %27.423.6 115.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72719,453 415.0%   
Fx outflow Rs m34,7006,065 572.2%   
Net fx Rs m46,02713,388 343.8%   
CASH FLOW
From Operations Rs m19,5488,120 240.8%  
From Investments Rs m-19,570-7,556 259.0%  
From Financial Activity Rs m8,642590 1,463.7%  
Net Cashflow Rs m8,9221,153 773.6%  

Share Holding

Indian Promoters % 54.1 74.1 73.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.9 274.1%  
FIIs % 27.7 9.1 304.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 13.9 73.4%  
Shareholders   69,601 49,328 141.1%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  STERLING BIOTECH  CADILA HEALTHCARE  ALEMBIC LTD  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks(The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 23, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ORCHID PHARMA LTD COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS